YDROCEPHALUS is a common neurological condition characterized by pathological dilation of the cerebral ventricles. It is usually caused by obstruction of cerebrospinal fluid flow. Axonal damage in the periventricular white matter is one of the earliest pathological consequences of ventricular dilation in humans and animals. The pathophysiology of hydrocephalus-induced brain damage is multifactorial, with contributions made by gradual physical stretching and compression of tissues, chronic ischemia, alterations in neurochemical function, and possible accumulation of metabolic waste products.
YDROCEPHALUS is a common neurological condition characterized by pathological dilation of the cerebral ventricles. It is usually caused by obstruction of cerebrospinal fluid flow. Axonal damage in the periventricular white matter is one of the earliest pathological consequences of ventricular dilation in humans and animals. The pathophysiology of hydrocephalus-induced brain damage is multifactorial, with contributions made by gradual physical stretching and compression of tissues, chronic ischemia, alterations in neurochemical function, and possible accumulation of metabolic waste products. 12, 32 The damage is progressive with a time course measured in days to months. The mechanism of brain damage bears some similarities to those associated with trauma and stroke, in which damage occurs more rapidly. It has been postulated that acute physical trauma and ischemic injury to axons both alter membrane permeability, leading to local electrolyte disturbances, influx of calcium, and activation of calpains. 7, 41 The calpains are cytoplasmic enzymes that cause proteolytic damage to the axonal cytoskeleton, accompanied by impairment of axonal transport and, ultimately, disconnection. 35 The same process occurs when axons of the optic nerve are gradually stretched. 30 Nimodipine, an antagonist of L-type voltage-sensitive calcium channels that cross the blood-brain barrier, has been shown to be protective in a range of neurological disorders. It has effects both on CBF and neuronal function. 38 In short-term experiments, nimodipine has been shown to reduce brain damage following experimental stroke and seizures in several animal models. 37, 38 Long-term oral administration is associated with improved behavioral outcome in hypertensive rats. 28 Administration of nimodipine to humans within 18 hours after stroke is associated with a reduced probability of deterioration. 2 Nimodipine has displayed proven efficacy in neurosurgical patients with subarachnoid hemorrhage 17 and as a prophylactic agent against migraine headaches in children. 3 In an experimental model of hydrocephalus induced by injection of kaolin into the cisterna magna of immature rats, we have demonstrated the presence of abnormal quantities of soluble ionic calcium and activated calpains in the periventricular white matter. 11 Diminished blood flow has been demonstrated in the white matter of hydrocephalic rats. 29 We hypothesized that administration of nimodipine to rats could ameliorate the abnormalities associated with severe infantile hydrocephalus.
Animal Preparation
Sprague-Dawley rats bred locally were delivered to our facility at age 3 weeks (weight 43-61 g). After initial behavioral testing, anesthesia was induced in the rats by intramuscular injection of ketamine/xylazine (90:10 mg/kg). Each rat's neck was shaved and, under aseptic conditions, a 27-gauge needle was inserted percutaneously into the cisterna magna. Sterile kaolin suspension (0.05 ml; 250 mg/ml in 0.9% saline) was injected slowly to induce hydrocephalus. Control animals received a sham injection consisting of needle insertion only. In response to this quantity of kaolin, young rats experience gross enlargement of the cerebral ventricles and head and die within 4 to 6 weeks. The rats were housed in standard cages (initially four animals/cage and later two animals/cage as their sizes increased) and provided with a normal 12-hour day/night lighting schedule with free access to water and pelleted food from the cage tops. As the rats became impaired, food and water was provided on the cage floors.
Magnetic Resonance Imaging
Magnetic resonance studies were performed using an MR imager equipped with a 21-cm bore magnet operating at a field of 7 tesla to obtain T 2 -weighted images of the brain in the coronal plane. The widths of the lateral ventricles and cerebrum were measured in the rostral cerebrum immediately anterior to the third ventricle. Frontal horn size was expressed as a ratio determined by dividing the total width of the ventricles by the width of the cerebrum. These methods have been previously described in detail.
14 Rats underwent MR imaging no more than 24 hours before commencement of drug treatments or before receiving an overdose of anesthesia.
Behavioral Testing
All testing was done in a blinded manner. The rats were weighed twice per week. On a weekly basis, beginning before kaolin injection and continuing during the development of hydrocephalus and during the drug-treatment phases, several specific behavioral tests were performed. The rats were always tested in the same order and a given rat was tested at the same time of day from week to week.
On the 1st testing day of each week, the rats were observed in an open field for a period of 3 minutes to assess arousal, grooming, and gait by using a previously validated set of parameters. 33 Quantitative monitoring of spontaneous activity was then performed for 15 minutes in a square enclosure (43 ϫ 43 cm) with 15 infrared beams (spaced every 3 cm) along the floor in each of two horizontal directions and a third set of similarly spaced beams 8.5 cm above the floor. Total and ambulatory beam breaks were counted, the latter being defined as an interruption in a series of adjacent beams, as well as the frequency of vertical exploration activity. Finally, ambulatory agility was assessed using a rotating cylinder (7-cm diameter) in two separate trials. First, motor endurance at a constant speed of 5 rpm was assessed for a maximum of 3 minutes. Second, the ability to stay on the drum at an accelerating speed was tested beginning at 2.5 rpm and increasing at a rate of 0.1 rpm every second for up to 3 minutes. The time was measured from the moment the rat was placed on the rotating cylinder until it fell off. The rotating cylinder test is complex and involves proprioceptive, tactile, vestibular, and motor functions.
On the 2nd testing day of each week, physical swimming ability was tested in a 20-cm-deep 15-cm-wide water trough by measuring the time it took a rat to swim 150 cm. Memory was then assessed in a modified water maze test by using a 90-cm-diameter pool (filled with 22˚C water) that contained a 13-cm-round hidden platform 1 cm below the water surface as previously described. 14, 26 Testing took place in a dimly lit room with a single wall illuminated to provide directional cues. The rats were placed in the center of the pool and allowed to swim until they found the platform. A trial consisted of four attempts to find the platform, each attempt beginning with the rat facing a different quadrant. If the rat failed to complete the task in 60 seconds, it was given a 60-second rest period before the next attempt. Three trials were performed during the course of the day; each was separated by a 2-hour interval. The durations of the four attempts were averaged for each trial. The rats' motor ability and cognitive search strategies were reflected in their performance during the first trial of each day. If the rats were capable of learning, the mean swimming time was expected to decrease progressively during the course of the day.
Histopathological and Biochemical Studies of Brains Following Drug Treatments
At the end of the 2-week drug-treatment period and following the final MR imaging session, the rats were given an overdose of pentobarbital, their vascular systems were cleared by transcardiac perfusion with ice-cold 0.1 M phosphate-buffered saline, and their brains were removed quickly. The brains were cut coronally at the level of the optic chiasm. Samples of the corpus callosum, parietal lobe, and frontal lobe were dissected and frozen in liquid nitrogen, after which they were stored at Ϫ80˚C. The remaining pieces were immersion fixed in 10% buffered formalin. The anterior cerebrum, cut coronally at the level of the optic chiasm, was embedded in paraffin. Sections were stained with hematoxylin and eosin, as well as solochrome cyanine for visualization of myelin. Immunohistochemical methods were used to detect MBP (rabbit polyclonal anti-MBP, 1:300 dilution), GFAP (rabbit polyclonal anti-GFAP, 1:1000 dilution), and NF (mouse monoclonal anti-NF, 1:1000 dilution). Following overnight incubations, primary antibodies were linked with appropriate biotinylated secondary antibodies, followed by streptavidin-peroxidase and diaminobenzidine. Corpus callosum thickness was measured in the midline and adjacent to the cingulum on MBPlabeled sections. Reactive astrogliosis was quantified by the intensity of GFAP immunoreactivity on the slides by using a spotlightmetering system of a microscope as an optical densitometer. At 20 ϫ objective magnification, the spot meter registered a circular area 50 µm in diameter. With consistent illumination and filter settings for transmitted light, all brain sections were sampled at four different points along the corpus callosum, two areas in the fimbria, and four different areas in the frontal cortex. Damaged axons were counted in the corpus callosum on NF-labeled sections.
As described previously in detail, 15, 16 brain homogenates were used to quantify myelin-and oligodendrocyte-related enzymes by biochemical means, and GFAP, synaptophysin, and MBP by using Western blots. Two or three replicated studies were performed to ensure reproducibility and allow meaningful statistical analysis.
Nimodipine Treatment
Pilot Experiment. A pilot experiment was performed to determine the nimodipine dose that would be safe and potentially beneficial. Kaolin was injected into the cisterna magna of 36 rats. Two weeks later, MR imaging was performed to ensure that the rats had ventriculomegaly. The rats were stratified according to ventricle size and were assigned to one of four treatment groups ensuring an even distribution of ventricle sizes across groups. Nimodipine was administered every 12 hours, beginning 2 weeks after induction of hydrocephalus and continuing for a period of 2 weeks. Initially a polyethylene glycol/ethanol solvent was used to dissolve the drug; however, because of renal acidosis, this was switched after a few days to 50% dimethyl sulfoxide and 10% ethanol in a 0.9% saline solution. Four groups, nine animals in each group, were used: 1) subcutaneous solvent vehicle; 2) low-dose subcutaneous nimodipine (2 mg/kg/day); 3) high-dose subcutaneous nimodipine (20 mg/kg/day); and 4) high-dose oral nimodipine (20 mg/kg/day delivered as an aqueous suspension by gavage). Selection of these initial doses was based on reported benefits of nimodipine in hypertensive adult rats (long-term oral dosage of approximately 25 mg/day), 28 and in adult rats with middle cerebral artery occlusion (parenteral dose of 1.2 mg/kg given during the acute period). 4 Behavioral testing was conducted weekly before and after starting treatment. The rats underwent MR imaging of the brain 4 weeks after kaolin injection and were then killed. In this pilot experiment there were no significant intergroup differences in ventricle size shown on MR images obtained immediately before initiation of drug treatment. Subsequent weight gain was the worst in the animals that received the 20 mg/kg/day parenteral dose of nimodipine (final weight 244 Ϯ 28 g in the treated group compared with 265 Ϯ 15 g in the control group) and the incidence of mortality in rats receiving parenteral doses was higher (four of nine animals that received a parenteral high dose of nimodipine, five of nine animals that received a parenteral low dose of nimodipine, two of nine animals that received an oral dose of nimodipine, and two of nine animals in the untreated control hydrocephalic group). Focal areas of skin sloughing were noted at some injection sites in rats that received high-dose injections. Twenty-three rats survived the entire treatment period. Following 2 weeks of drug treatment, there were no differences in ventricle size on the final MR image or in results of the swim maze test or activity monitoring. Continuous low-speed roller endurance was better in rats that received the 2 mg/kg/day parenteral dose (115 Ϯ 6 seconds; p = 0.063) or the 20 mg/kg/day oral dose (82 Ϯ 20 seconds) than in those that received no treatment (60 Ϯ 24 seconds). Histopathological examination of the brains and assays of brain composition indicated no differences in myelin content, reactive astrogliosis, or quantity of damaged axons. Surprisingly, whereas the other drug doses were associated with greater cerebral synaptophysin content than untreated controls (not significantly different), the 20 mg/kg/day parenteral dose was associated with lower (74% of control value; p = 0.34) optical density of cerebral synaptophysin content on Western blots. Overall, these data indicate that young hydrocephalic rats might benefit behaviorally from 2-week treatment with moderate doses of nimodipine, whereas the highest dosage (20 mg/kg/day) was associated with side effects including, perhaps, delayed brain development.
Final Experiment. Because the results of the pilot experiment indicated potential benefit, but also potential problems with the drug-delivery system, a more refined experiment was performed. Forty rats underwent prehydrocephalus behavioral testing before they received kaolin injections (weight at time of injection 86.9 Ϯ 1.3 g). Two weeks later MR imaging of the brain was performed. Two rats with normal-sized small ventricles were excluded. The rats were stratified according to ventricle size. Descending through the list of ventricle size, the rats were assigned alternately to control or treatment groups in an attempt to ensure that the initial ventricle size was similar. Nimodipine was dissolved in sterile 50% dimethyl sulfoxide and 5% ethanol in an aqueous 0.9% saline solution at a concentration of 150 mg/ml. Osmotic minipumps (Alzet model 2002; ALZA Corp., Palo Alto, CA) were loaded with drug solution or vehicle and coded so that the behavioral testing and subsequent analyses were performed in a blinded fashion. Anesthesia was induced in the rats by an intramuscular injection of ketamine/xylazine (90 and 10 mg/kg) and the pump was inserted subcutaneously on the back above the scapulae by using aseptic technique. The skin incision was closed with staples, which were removed 1 week later. Before surgery and every 12 hours the following day, the rats received three doses of cefazolin sodium (10 mg/kg) delivered subcutaneously as prophylaxis for infection. Hydrocephalic rats were treated with continuous subcutaneous infusion of nimodipine (1.8 mg/day) or vehicle for 2 weeks. The weight of the rats at the beginning of treatment was 134.6 Ϯ 3.3 g and, therefore, the dosage of nimodipine started at approximately 13 mg/kg/day. Because the rats gained weight while receiving a constant infusion of nimodipine from the inplanted pumps, the delivered dosage gradually decreased to approximately 8 mg/kg/day.
Statistical Analysis
All data are presented as means Ϯ SEMs. For Western blots, the densitometric values were normalized to those of control values and percentages of change relative to control values are indicated. Quantitative data were analyzed to confirm a normal distribution. Statistical analysis consisted of analysis of variance with post hoc Bonferroni-Dunn calculations for intergroup comparisons for the pilot experiment and the one-tailed Student t-test for the final experiment. The paired t-test was used to compare the change in the ventricle size index between pre-and posttreatment MR images. Absolute and relative changes were also assessed. Alpha levels were adjusted to take into consideration the fact that multiple parameters were being analyzed. Statistical significance is defined as a probability value less than 0.05. Statistical computer software was used for analysis.
Sources of Supplies and Equipment
Nimodipine was obtained from Research Biochemical International (Natick, MA). The rabbit polyclonal anti-MBP and the rabbit polyclonal anti-GFAP were purchased from Dako Corp. (Carpinteria, CA), and the mouse monoclonal anti-NF was bought from Sternberger Moncolonal Inc. (Baltimore, MD). StatView 5 statistical software was obtained from SAS Institute (Cary, NC).
The Biospec/3 MR imager was procured from Buker (Karlsruhe, Germany). The apparatus used to assess the rats' spontaneous activity (Opto-Varimex) and the rotating cylinder used to assess their ambulatory agility (Economex) were purchased from Columbus Instruments (Columbus, OH). The Microphot FX microscope, obtained from Nikon (Tokyo, Japan), was used in the histopathological studies.
Results
General behavioral changes, ventricle size changes, and neuropathological changes in young rats have been described in previous publications. [14] [15] [16] Following kaolin injection, young rats exhibit slow weight gain, progressive cerebral ventricle and head enlargement, ataxia, and lethargy after 3 to 4 weeks. Typically, the animal's perfor- mance on behavioral tests remains stable or improves as a consequence of maturation and learning during the first 2 weeks after kaolin injection; however, by 4 weeks after kaolin injection, rats tend to perform less well in motor and memory tests because the hydrocephalus continues to progress. If left alone they die after 4 to 6 weeks.
Hydrocephalic rats received continuous subcutaneous infusion of nimodipine at a dose of 1.8 mg/day by osmotic minipumps beginning 2 weeks after kaolin injection and continuing for 2 weeks. These rats were studied before and after kaolin injection from age 3 weeks to 7.5 weeks. Two rats died before commencement of drug treatment and two others during the drug-treatment period, leaving the control and nimodipine treatment groups with 18 animals each.
Behavioral Outcomes
Behavioral data used to compare the two groups are summarized in Table 1 . There was no difference in weight gain. A comparison of the two groups revealed that the ventricle size index was not significantly different before and after drug treatment. Both groups exhibited significant (p Ͻ 0.05, paired t-tests) progression of ventriculomegaly during the treatment period. There were no differences in the crude behavioral parameters observed in the open field (data not shown). There was no significant difference in total spontaneous activity, ambulatory activity, or vertical exploration at any time point, although at the end of the experiment the treated rats tended to be less active, indicating that they habituated better in the activity monitor. Performance on the rolling cylinder was the same as that observed before initiation of treatment. Subsequently, the nimodipine-treated rats were able to stay on the cylinder significantly longer than the untreated rats, both at constant speed ( Fig. 1 ) and accelerating speed (Table 1). The nimodipine-treated rats were also able to swim significantly faster in the straight water trough. The latency period before finding the hidden platform in the pool was greatest during the first trial of young rats prior to kaolin injections. All rats displayed significant improvements during subsequent trials performed the same day, indicating that they were capable of learning the task (Table 1). Although straight trough swim speed improved only slightly, all rats demonstrated further improvements during the hidden platform swim test with decreased latencies 1 and 2 weeks after kaolin injection. This suggests that they had retained memory of the task from one week to the next. Unexpectedly, when data were analyzed, we found that the nimodipine-treated animals tended to perform better in the hidden platform swim test prior to the start of treatment. In retrospect, this may be because the rats were assigned to the treatment group on the basis of ventricular size alone. During Weeks 3 and 4 after the kaolin injection, untreated control rats deteriorated and exhibited significantly longer latencies than those observed at earlier time points. Furthermore, they displayed no improvement from the first to last test on individual testing days, suggesting that they had poor recall of the task. Nimodipine-treated hydrocephalic rats, on the other hand, did not deteriorate during the treatment period and had persistently brief latency times (Fig. 2) , which were significantly better than those of the untreated rats. The hidden platform results can only be explained partly on the basis of the rats' physical ability to swim; nimodipinetreated rats swam approximately 20% faster in the straight trough but found the platform approximately 70% faster. The times of treated rats were similar to those set by nonhydrocephalic rats of the same age (data from previous experiments 14 ).
Morphological and Biochemical Findings
Morphological and biochemical analysis of brains from hydrocephalic rats at the end of the experiment also revealed a significant benefit from nimodipine treatment. The data are summarized in Table 2 . The corpus callosum was significantly thicker in nimodipine-treated rats. The proportion of myelin content (based on immunoblot analysis and enzyme assays) to total protein did not differ. The active production of myelin by oligodendrocytes, as determined by using an assay of uridine diphosphate-galactose ceramide galactosyltransferase activity, did not differ. Cerebral content of synaptophysin and GFAP, and immuno-
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Nimodipine and hydrocephalus 791 FIG. 1. Line graph showing the time in seconds (mean Ϯ SEM) that young rats remained on a rolling cylinder at constant speed. Times are shown for trials performed before kaolin injection, during the 2 weeks prior to treatment during which hydrocephalus was developing, and during the 2 weeks after initiation of nimodipine treatment. Endurance initially improved as the rats matured and then began to deteriorate as the hydrocephalus became severe in untreated rats (control group, black line). Nimodipine-treated hydrocephalic rats (gray line), on the other hand, exhibited no loss of ability and performed significantly better (*p Ͻ 0.001) than control rats during the final week.
histochemical measures of reactive astrocytes and the quantity of swollen axons did not differ between the two groups. There was no microscopic evidence that the kaolin caused inflammation in the brain adjacent to the subarachnoid collection or had adversely affected arteries at the base of the brain. Although these were embedded in a collection of fibrous tissue and kaolin-containing macrophages, there was no inflammation in the vessel wall and no apparent constriction of the lumen.
Discussion
The use of young rats with kaolin-induced hydrocephalus in these experiments shows that nimodipine treatment protects motor and cognitive behaviors, as well as periventricular white matter from the adverse affects of hydrocephalus. The pathological changes in this model are concentrated in the periventricular white matter, including the corpus callosum. The earliest change is a delay in myelination 15 followed by progressive axonal injury accompanied by reactive astroglial and microglial changes. 14, 16, 46 We have shown that calcium accumulates in the region of injury and that proteolytic calpains are present and activated in the white matter. 11 Axonal stretch injury causes influx of calcium into the axolemma at least in part through L-type calcium channels. 27, 36 This, in turn, activates calpains that can damage the axoskeletal proteins through proteolysis. The ultimate result is axonal disconnection. 31 In addition to mechanical injury to axons, there is clear evidence for hypoperfusion and chronic ischemia in the white matter of hydrocephalic brains. 6, 9 Hydrocephalus has been shown to impinge on both capillaries and larger vessels including arterioles. 13, 34 Nimodipine blocks voltage-sensitive L-type calcium channels, which are located on neurons, axons, reactive astrocytes, and vascular smooth muscle. 18, 44 In doses comparable to those used in this study, nimodipine reduces acute infarction volume following middle cerebral artery occlusion in adult rats, 4 reduces motor neuron degeneration following hypoglossal nerve axotomy in 1-day-old rats, 42 and inhibits epileptic kindling in 16-day-old rats. 45 Administered long term in food, it reduces behavioral deterioration and vascular changes in aged and hypertensive rats. 10, 28 Nimodipine does not, however, protect hippocampal neurons of rats against the effects of global cerebral ischemia. 8 Clinically, nimodipine treatment reduces vasospasm-related ischemic events following subarachnoid hemorrhage 17 and is possibly beneficial to stroke patients necessary for young rats to find a hidden platform in the water pool test during the first of three daily trials. Times are shown for trials performed before kaolin injection, during the 2 weeks prior to treatment during which hydrocephalus was developing, and during the 2 weeks after initiation of nimodipine treatment. As the rats matured, the speed with which they found the platform from week to week improved. Prior to treatment the two groups performed equally well. Performance of untreated hydrocephalic rats (control group, black line) then began to deteriorate as the hydrocephalus became severe. Nimodipine-treated hydrocephalic rats (gray line), on the other hand, continued to improve and performed significantly better (*p Ͻ 0.001) than control rats. when administered less than 18 hours after the event. 2, 23 In children, chronic oral prophylaxis with nimodipine reduces the incidence of migraine headaches.
3 Nimodipine appears to be safe for use in pediatric head trauma, 39 although it is not clearly beneficial. The related calciumchannel blocking agent, nicardipine, has been given to children with moyamoya disease to reduce cerebral ischemic events. 22 In cases of hydrocephalus, nimodipine has the potential ability to prevent pathological increases in intracellular and intraaxonal calcium 12 and to inhibit calcium-independent inducible nitric oxide synthase in reactive astroglia. 47 However, nimodipine affects cerebral blood vessels at 10-to 100-fold lower concentrations than it affects synaptosomes and cultured neural cells. 37, 38 Thereby, it can increase CBF.
1 Therefore, we would predict that the beneficial effect of nimodipine on experimental hydrocephalus is through improved blood flow to the hypoperfused white matter, probably through its action on the smooth muscle of brain arterioles, although we do not yet have data to prove that conjecture. Restoration of nutrition would prevent the loss of oligodendrocytes, myelin, and axons 16 and might explain the preservation of corpus callosum thickness. Preservation of all components of the corpus callosum would explain the failure to detect relative changes in any individual cellular component.
To be useful, the safety profile of nimodipine must be determined. Our observation during the pilot experiment of reduced synaptophysin accumulation following intermittent high-dose parenteral nimodipine treatment is consistent with reports that calcium influx through L-type calcium channels is important for synaptogenesis. 25, 43 More work should be done to determine that nimodipine is beneficial in models of hydrocephalus that are not induced by kaolin. We cannot exclude the possibility that subarachnoid compartment inflammation in this model 40 alters the responsiveness of cerebral arteries.
Conclusions
Nimodipine protects cerebral white matter in immature rats against the damaging effect of kaolin-induced hydrocephalus, probably through improvement of CBF, but also potentially through reduction of calcium-activated proteolysis. 11 Considering previous experiences with nimodipine, a protective effect is not surprising because hydrocephalic brain damage occurs in part through mechanisms similar to those implicated in brain ischemia and trauma. 5, 24 Pharmacological intervention before surgical shunting of CSF would possibly benefit infants suffering from hydrocephalus, in whom a shunt cannot be placed immediately. 19, 21 It might also be of value to adults with chronic low ("normal")-pressure hydrocephalus, in whom the value of a shunt is questionable, particularly in consideration of the possible potentiation of hydrocephalic brain damage by hypertension. 20 Unlike cerebral trauma and ischemic injury, in which damage occurs over a period of seconds to minutes, hydrocephalus might be particularly amenable to supplemental pharmacological therapy, because the damage it produces is gradual and progressive over a period of days to months.
